Screener
Kyverna Therapeutics, Inc. KYTX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $32,194 | $124,093 |
| Available-for-sale marketable securities | 204,252 | 155,160 |
| Prepaid expenses and other current assets | 5,280 | 3,700 |
| Total current assets | 241,726 | 282,953 |
| Restricted cash | 551 | 551 |
| Property and equipment, net | 1,343 | 1,546 |
| Operating lease right-of-use assets | 8,192 | 3,568 |
| Finance lease right-of-use assets | 198 | 305 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s total current assets?
- Kyverna Therapeutics, Inc. (KYTX) reported total current assets of $241.73M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s total current assets changed year-over-year?
- Kyverna Therapeutics, Inc.'s total current assets decreased by 2.4% year-over-year, from $247.65M to $241.73M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s total current assets?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s total current assets has grown at a 116.0% compound annual growth rate (CAGR), from $60.66M to $282.95M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Kyverna Therapeutics, Inc.'s total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude